{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T07:51:16Z","timestamp":1753602676312},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.encep.2013.11.002","type":"journal-article","created":{"date-parts":[[2014,11,16]],"date-time":"2014-11-16T22:23:46Z","timestamp":1416176626000},"page":"260-265","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Troubles anxieux r\u00e9sistants\u00a0: revue des strat\u00e9gies de traitements m\u00e9dicamenteux"],"prefix":"10.1016","volume":"41","author":[{"given":"G.","family":"Ammar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.J.","family":"Naja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pelissolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2013.11.002_bib0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.encep.2007.12.008","article-title":"TOC r\u00e9sistant\u00a0: caract\u00e9ristiques cliniques, facteurs pr\u00e9dictifs et influence des temp\u00e9raments affectifs","volume":"34","author":"Hantouche","year":"2008","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2013.11.002_bib0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.euroneuro.2005.04.002","article-title":"Size and burden of social phobia in Europe","volume":"15","author":"Fehm","year":"2005","journal-title":"Eur Neuropsycho Pharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0015","first-page":"510","article-title":"\u00c9pid\u00e9miologie des troubles anxieux en psychiatrie lib\u00e9rale\u00a0: pr\u00e9valences, comorbidit\u00e9 et retentissement (\u00e9tude DELTA)","volume":"28","author":"P\u00e9lissolo","year":"2002","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2013.11.002_bib0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.encep.2011.02.006","article-title":"Id\u00e9ation et conduites suicidaires en France\u00a0: pr\u00e9valence sur la vie et facteurs de risque dans l\u2019\u00e9tude ESEMeD","volume":"38","author":"Nicoli","year":"2012","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2013.11.002_bib0025","article-title":"Clinical practice guidelines. Management of anxiety disorders","volume":"51","author":"Canadian Psychiatric Association","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.encep.2008.04.004","article-title":"Efficacit\u00e9 et tol\u00e9rance de l\u2019escitalopram dans les troubles anxieux\u00a0: revue de la litt\u00e9rature","volume":"34","author":"Pelissolo","year":"2008","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2013.11.002_bib0035","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Troubles obsessionnels-compulsifs (TOC) r\u00e9sistants\u00a0: prise en charge et place de la neurochirurgie fonctionnelle. 2005."},{"key":"10.1016\/j.encep.2013.11.002_bib0040","first-page":"280","article-title":"Int\u00e9r\u00eat de la fluox\u00e9tine dans les troubles obsessionnels et compulsifs de l\u2019adulte\u00a0: revue de la litt\u00e9rature","volume":"27","author":"Etain","year":"2001","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2013.11.002_bib0045","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog Neuropsycho Pharmacol Biol Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0050","first-page":"5","article-title":"American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0055","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0060","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopsych.2006.12.014","article-title":"Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?","volume":"61","author":"Denys","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","article-title":"Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study","volume":"28","author":"Kordon","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0070","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","article-title":"A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder","volume":"55","author":"Shapira","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0080","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.08m04369","article-title":"A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder","volume":"70","author":"Matsunaga","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(00)00065-1","article-title":"Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo-controlled trial","volume":"10","author":"Dannon","year":"2000","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0090","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S1092852912000065","article-title":"Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial","volume":"15","author":"Mowla","year":"2010","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.encep.2013.11.002_bib0100","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/11635850-000000000-00000","article-title":"Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Askari","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2013.11.002_bib0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.encep.2013.11.002_bib0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.encep.2013.11.002_bib0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0013-7006(07)91562-6","article-title":"Le traitement pharmacologique de l\u2019anxi\u00e9t\u00e9 g\u00e9n\u00e9ralis\u00e9e\u00a0: utilisation rationnelle et limitations","volume":"33","author":"Boulenger","year":"2007","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2013.11.002_bib0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2005.07.005","article-title":"Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo-controlled study","volume":"59","author":"Pollack","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00213-008-1087-x","article-title":"Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings","volume":"197","author":"Simon","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.encep.2013.11.002_bib0130","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1176\/appi.ajp.159.10.1777","article-title":"Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study","volume":"159","author":"Stein","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biopsych.2004.11.039","article-title":"Adjunctive risperidone in the treatment of chronic combat-related post-traumatic stress disorder","volume":"57","author":"Bartzokis","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004850-200301000-00001","article-title":"Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms","volume":"18","author":"Hamner","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0145","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jama.2011.1080","article-title":"Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial","volume":"306","author":"Krystal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.encep.2013.11.002_bib0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hup.2238","article-title":"Olanzapine monotherapy in post-traumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study","volume":"27","author":"Carey","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/appi.ajp.160.2.371","article-title":"Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study","volume":"160","author":"Raskind","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0160","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0165","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4088\/JCP.v66n0610","article-title":"Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a cross-over study","volume":"66","author":"Li","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2013.11.002_bib0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0175","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","article-title":"Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"31","author":"Muscatello","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0180","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","article-title":"Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double-blind clinical trial)","volume":"29","author":"Sayyah","year":"2012","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.encep.2013.11.002_bib0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hup.1169","article-title":"The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study","volume":"26","author":"Selvi","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.encep.2013.11.002_bib0190","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v65n0418","article-title":"Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial","volume":"65","author":"Bystritsky","year":"2004","journal-title":"J Clin Psychiatry"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700614000402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700614000402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T15:23:40Z","timestamp":1538061820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700614000402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0013700614000402"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2013.11.002","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Troubles anxieux r\u00e9sistants\u00a0: revue des strat\u00e9gies de traitements m\u00e9dicamenteux","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2013.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}